据统计，下周将有25股面临解禁（已发布解除或流通公告），按照最新收盘价计算，合计解禁市值 795.29亿元。联影医疗下周将有2.31亿股上市流通，主要为首发原股东限售股份，解禁市值达295.41亿 元。格科微的解禁规模次之，下周将有10.5亿股上市流通，主要为首发原股东限售股份，解禁市值达 163.91亿元。相比之下，兰剑智能、五新隧装、高新发展、泰和新材等10股的解禁压力较小，解禁市值 均不足亿元。从解禁比例来看，华兰疫苗的解禁比例居首，达76.37%；中触媒、格科微、路维光电、 汇成股份等解禁比例也居前。（证券时报） ...

Group 1 - The core point of the news is that Sichuang Medical (300078) has received a notice from the Hangzhou Public Security Bureau regarding an investigation into alleged fraudulent issuance of securities, and the company will cooperate with the investigation [1] - As of August 15, 2025, the investigation is still in the police investigation stage, and no clear conclusion has been reached [1] - The company has committed to timely information disclosure based on the progress of the case [1] Group 2 - Sichuang Medical's stock price has increased by 30.59% year-to-date, and the number of shareholders has grown by 51.39% compared to the end of 2024, reaching 73,800 [3] - Next week, 25 stocks will face a total unlock market value of 795.29 billion, with significant unlocks from companies like United Imaging Healthcare and GeKong Microelectronics [5][6] - Among the stocks facing unlock, some have seen institutional research, including New Coordinates and Leshan Electric Power, which recently reported on their technological advancements and operational updates [10]

Summary of Key Points Core Viewpoint - Next week, 25 stocks will face lock-up expiration, with a total market value of 79.529 billion yuan based on the latest closing prices [1]. Group 1: Lock-up Expiration Details - Among the stocks facing expiration, United Imaging Healthcare will have 231 million shares released, primarily from original shareholders, with a market value of 29.541 billion yuan [1]. - GeKong Microelectronics follows with 1.05 billion shares to be released, also from original shareholders, amounting to a market value of 16.391 billion yuan [2]. - In contrast, stocks like LanJian Intelligent, WuXin Tunnel Equipment, GaoXin Development, and TaiHe New Materials have relatively low lock-up pressure, with market values below 100 million yuan [3]. Group 2: Lock-up Ratio and Performance - Hualan Vaccine has the highest lock-up ratio at 76.37%, with other companies like ZhongChuang Catalyst, GeKong Microelectronics, LuWei Optoelectronics, and HuiCheng Shares also showing significant ratios [4]. - The 25 stocks facing lock-up expiration have seen an average increase of 3.93% since August, with LuWei Optoelectronics leading with a 29.48% increase [8]. - Stocks that have declined include WuXin Tunnel Equipment, United Imaging Healthcare, YiDian TianXia, and XinYa Electronics, with XinYa Electronics experiencing the largest drop of 13.83% [8]. Group 3: Institutional Research and Company Updates - New Coordinates and Leshan Electric Power have recently undergone institutional research, with New Coordinates developing patented technologies for environmentally friendly rust removal and phosphating processes [9]. - Leshan Electric Power reported that its 100MW/200MWh electrochemical energy storage station successfully connected to the grid and will enter commercial operation after a three-month testing period [9]. Group 4: Earnings Forecasts - Among the stocks facing lock-up expiration, three have released earnings forecasts. TaiHe New Materials anticipates a net profit of approximately 25 million to 35 million yuan, reflecting a year-on-year decrease of 70.21% to 78.72% [10]. - KeMa Technology expects an increase in earnings, while Leshan Electric Power reported a total revenue of 1.623 billion yuan for the first half of the year, a year-on-year increase of 1.94%, but with a net profit decline of 14.55% [11].

Core Viewpoint - Next week, 25 stocks will have their restrictions lifted, with a total market value of 79.529 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - United Imaging Healthcare will have 231 million shares available for trading, primarily consisting of original shareholders' restricted shares, with a market value of 29.541 billion yuan [1] - GeKong Microelectronics follows with 1.05 billion shares set to be unlocked, also mainly from original shareholders' restricted shares, amounting to a market value of 16.391 billion yuan [1] Group 2: Unlocking Ratios - Hualan Biological Engineering has the highest unlocking ratio at 76.37% [1] - Other companies with significant unlocking ratios include Zhongchu Catalyst, GeKong Microelectronics, Luvi Optoelectronics, and Huicheng Co., Ltd. [1]

Core Viewpoint - The announcement details the lifting of restrictions on a significant number of shares of Hualan Biological Engineering Co., Ltd., allowing for the circulation of 459 million shares, which accounts for 76.37% of the company's total share capital, effective from August 18, 2025 [2][5][23]. Group 1: Share Circulation Details - The restricted shares being released are part of the shares issued before the initial public offering (IPO) [2]. - The total number of shareholders involved in this release is two: Hualan Biological Engineering Co., Ltd. and Hong Kong Kecang Co., Ltd. [2][24]. - The total number of shares being released is 459,000,000, which represents 76.37% of the total share capital of the company [5][25]. Group 2: Share Capital Structure - As of the announcement date, the total share capital of the company is 601,027,500 shares, with 141,648,150 shares being unrestricted, accounting for 23.57% of the total [5]. - The company underwent a capital increase through a stock dividend distribution, resulting in an increase in total share capital from 400,010,000 shares to 600,015,000 shares [4]. Group 3: Compliance and Commitments - The shareholders lifting the restrictions have fulfilled their commitments made during the IPO process, ensuring compliance with relevant regulations [22]. - The commitments include not transferring or managing the shares for a specified period and adhering to regulations regarding share reduction [6][11]. Group 4: Clinical Trial Approval - Hualan Biological has received approval for clinical trials of its freeze-dried Hib vaccine, which is a significant step in its product development strategy [33]. - The vaccine aims to provide protection against invasive infections caused by Haemophilus influenzae type b, which is a major pathogen in children [34].

Core Viewpoint - Hualan Biological Vaccine Co., Ltd. has received implied approval for clinical trials of its "Lyophilized Haemophilus influenzae type b Conjugate Vaccine" aimed at preventing invasive diseases caused by Haemophilus influenzae type b [1] Company Overview - Hualan Biological Vaccine Co., Ltd. was established in 2005 and is located in Xinxiang City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 601.0275 million RMB and a paid-in capital of 360 million RMB [1] - Hualan Biological has made investments in 2 companies and participated in 980 bidding projects, holding 41 patents and 138 administrative licenses [1] Shareholder Information - Major shareholders include Hualan Biological Engineering Co., Ltd. with a 75% stake, Kecang Co., Ltd. with 10%, Henan Huaying Enterprise Management Consulting Partnership (Limited Partnership) with 9%, and Xinxiang Chenyi Qiming Management Consulting Partnership (Limited Partnership) with 6% [1]

Policy Developments - Shanghai has initiated the online listing for the first batch of traditional Chinese medicine centralized procurement expansion, with the application period from August 12 to August 29, 2025 [1] Drug and Device Approvals - Hualan Vaccine has received approval for clinical trials of its lyophilized Hib conjugate vaccine, which is expected to induce immune response against Hib [2] - Insmed announced that the FDA has approved its first-in-class oral drug Brinsupri for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older [3] - The National Medical Products Administration has received a market application for the intraocular injection of Bevacizumab from Fuhong Hanlin and Eddingpharm, marking the second such application in China [4] - Heng Rui Medicine has received approval for clinical trials of its innovative drug SHR-A2102 in combination with other treatments for recurrent/metastatic head and neck squamous cell carcinoma [5] Capital Market Activities - Inokang Medical Technology has started the listing guidance process with Huatai Securities, as disclosed by the China Securities Regulatory Commission [6] - Inokang was founded in 2014 by returnees and experienced professionals in the medical industry, and it has been recognized as a national high-tech enterprise [7] - Rejuve Bio announced a capital increase of 100 million yuan for its subsidiary ShunJing Biomedical Technology, with the company's stake decreasing from 45.5833% to 43.1842% [8] Industry Events - Zhifei Biological has completed the first nationwide vaccination of its quadrivalent influenza vaccine, highlighting the competitive landscape and market potential in China's influenza vaccine sector [10] - Zhonghui Bio's quadrivalent influenza vaccine has passed the preliminary review for inclusion in the national commercial health insurance innovative drug directory [11] - BeiGene anticipates that its drug Sotucumab will receive its first global approval by the end of 2026, with multiple milestone events expected soon [12] Public Sentiment Alerts - The re-registration application for Green Valley Pharmaceutical's mannitol sodium capsules has not been approved, indicating ongoing challenges for this controversial Alzheimer's drug [14] Shareholder Activities - Former Vice Chairman of Zhaoyan New Drug plans to reduce his holdings by up to 352.45 million shares due to personal financial needs, representing 0.4703% of the company's total share capital [15]

Group 1: Industry Developments - Shanghai has initiated the online listing for the first batch of traditional Chinese medicine centralized procurement expansion, with the application period from August 12 to August 29, 2025 [1] - The Shanghai Market Supervision Administration reported a significant decline in the illegal rate of medical advertisements over the past five years, dropping from 3.89% in 2020 to 1.57% in 2024, a decrease of approximately 60% [2] - The first FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), Brinsupri, has been announced by Insmed, marking a significant milestone in the treatment options available for this condition [3] - The National Medical Products Administration has received a market application for the intraocular injection of Bevacizumab, indicating progress in ophthalmic drug development [4] - Heng Rui Medicine has received approval for clinical trials of its innovative drug SHR-A2102 for the treatment of recurrent/metastatic head and neck squamous cell carcinoma [5] Group 2: Capital Market Activities - Inokang Medical Technology has started the listing guidance process with Huatai Securities, indicating its intention to go public [6] - Rejuvenation Bio announced a capital increase of 100 million yuan for its subsidiary, Shun Jing Biomedical Technology, with a share price set at 25 yuan per registered capital [7] - Innovation Medical holds a 40% stake in Bole Brain Machine, which focuses on core technology research and product design in the medical rehabilitation field [8] Group 3: Vaccine and Pharmaceutical Developments - Zhifei Biological has completed the first nationwide vaccination for its quadrivalent influenza vaccine, showcasing advancements in vaccine distribution [9] - Zhonghui Bio's quadrivalent influenza vaccine has passed the preliminary review for inclusion in the national commercial health insurance innovative drug directory [10] - BeiGene anticipates that its drug Sotukimab will receive its first global approval by the end of 2026, with multiple clinical trials underway [11] Group 4: Regulatory and Market Challenges - The re-registration application for Green Valley Pharmaceutical's mannitol sodium capsules has not been approved, posing challenges for this controversial Alzheimer's drug [12] - There have been reports of supply shortages and rising prices for the mannitol sodium capsules, indicating market pressures and patient access issues [13] - Zhaoyan New Drug's former vice chairman plans to reduce his holdings by up to 352,450 shares, reflecting personal financial needs [14]

Core Viewpoint - The company has received approval for clinical trials of its "lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine," which is aimed at preventing invasive infections caused by Hib bacteria [1][2]. Group 1: Clinical Trial Approval - The company's subsidiary, Hualan Biological Vaccine Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the Hib vaccine [1]. - The clinical trial application for the vaccine was accepted on May 21, 2025, and has met the requirements for drug registration [1]. - The vaccine is intended to prevent invasive infections such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis caused by Hib [1]. Group 2: Vaccine Development - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is in a lyophilized form [2]. - The vaccine is expected to induce an immune response against Hib, providing protection to the vaccinated individuals [2]. - The company is also developing a combination vaccine based on the DTP (diphtheria, tetanus, and pertussis) framework, with the Hib vaccine as one of its components [2].

（文章来源：证券日报） 证券日报网讯 8月13日晚间，华兰疫苗发布关于部分首次公开发行前已发行股份上市流通的提示性公告 称，本次上市流通的限售股为公司部分首次公开发行前已发行股份；本次解除限售股东户数共计2户， 为华兰生物工程股份有限公司和科康有限公司，解除限售的股份数量共计459，000，000股，占公司总 股本的76.37%。本次解除限售的股份上市流通日期为2025年8月18日（星期一）。 ...